Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of China Shineway Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Ms. Kang Limin ("**Ms. Kang**") has been appointed as an executive director of the Company, which will take effect from 1 November 2026.

Ms. Kang, aged 51, graduated from Hebei University of Economics and Business in 1999 with a bachelor's degree in economics before joining the Group, and is currently the financial director of Shineway Pharmaceutical Group Limited (an indirect wholly-owned subsidiary of the Company). Ms. Kang is a senior management accountant of the China Association of Chief Financial Officers and a senior international financial manager of the International Financial Management Association with extensive expertise in budget management, capital management, internal control development, tax compliance and financial reporting management. She has over 20 years of practical experience in finance, taxation and corporate management, as well as extensive experience in group-level financial management.

Saved as disclosed above, as at the date of this announcement, Ms. Kang does not hold any other position with the Company or other members of the Group. As at the date of this announcement, Ms. Kang (1) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (2) does not hold any other major appointments and professional qualifications; (3) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company; and (4) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has entered into an appointment letter with Ms. Kang for a term of two years commencing from 1 November 2026, and she will be subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the terms of her appointment, Ms. Kang is entitled to an annual director's remuneration of HK$500,000. She is eligible to receive performance-related discretionary bonus of a sum to be determined by the Board. The remuneration of Ms. Kang was determined by the Board with reference to the recommendation of the remuneration committee of the Company based on her experience, level of responsibilities as a Director and within the Group and the prevailing market conditions.

Saved as disclosed above, Ms. Kang has confirmed that there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and the Company is not aware of any other matters in relation to her appointment that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Ms. Kang in joining the Company.

By order of the Board
China Shineway Pharmaceutical Group Limited
Lee Bun Ching Terence
Company Secretary

Hong Kong, 30 October 2026

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang and Mr. Li Huimin; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Mr. Liu Shun Fai, Mr. Yew Yat On and Ms. Wang Guihua.